Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 18Unknown 4Terminated 3Withdrawn 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Multiple Myeloma 112Recurrence 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Neoplasms 14Neoplasms, Plasma Cell 13Leukemia 10Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7Vomiting 6Prostatic Neoplasms 6Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Nausea 5Lung Neoplasms 5Pancreatic Neoplasms 3Lymphoma, Follicular 3Immunoglobulin Light-chain Amyloidosis 3Hematologic Neoplasms 3Hematologic Diseases 3Glioblastoma 3Amyloidosis 3Smoldering Multiple Myeloma 2Renal Insufficiency 2Oligodendroglioma 2Myelodysplastic Syndromes 2

Interventions

Rituximab 59Cyclophosphamide 29fludarabine phosphate 20Bortezomib 16Filgrastim 15Tacrolimus 12Mycophenolic Acid 12Methotrexate 12Radiotherapy 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 11Antilymphocyte Serum 11Whole-Body Irradiation 10fludarabine 8Etoposide 8venetoclax 7sargramostim 7idelalisib 7ibritumomab tiuxetan 7Melphalan 7Lenalidomide 7Cord Blood Stem Cell Transplantation 7Busulfan 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Granulocyte Colony-Stimulating Factor 6obinutuzumab 5Gemcitabine 5umbralisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Follicular × Dexamethasone × Clear all
NCT04156828 2023-06-29

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

University of Washington

Phase 1 Terminated
12 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00562965 2018-01-09

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Pfizer

Phase 3 Terminated
29 enrolled 14 charts
Lymphoid

Lymphoma, Follicular

NCT00510887 2014-05-12

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Duke University

Phase 2 Terminated
14 enrolled 9 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡